The COVID pandemic prompted a significant increase in the utilization of telemedicine (TM) for substance use disorder (SUD) treatment. As we transition towards a “new normal” policy, it is crucial to comprehensively understand the evidence of TM in SUD treatment. This scoping review aims to summarize existing evidence regarding TM's acceptability, quality, effectiveness, access/utilization, and cost in the context of SUD treatment in order to identify knowledge gaps and inform policy decisions regarding TM for SUDs.
Method
We searched studies published in 2012–2022 from PubMed, Cochrane Library, Embase, Web of Science, and other sources. Findings were synthesized using thematic analysis.
Results
A total of 856 relevant articles were screened, with a final total of 42 articles included in the review. TM in SUD treatment was perceived to be generally beneficial and acceptable. TM was as effective as in-person SUD care in terms of substance use reduction and treatment retention; however, most studies lacked rigorous designs and follow-up durations were brief (≤3 months). Telephone-based TM platforms (vs video) were positively associated with older age, lower education, and no prior overdose. Providers generally consider TM to be affordable for patients, but no relevant studies were available from patient perspectives.
Conclusions
TM in SUD treatment is generally perceived to be beneficial and acceptable and as effective as in-person care, although more rigorously designed studies on effectiveness are still lacking. Access and utilization of TM may vary by platform. TM service quality and costs are the least studied and warrant further investigations.
HedegaardHMiniñoAMSpencerMR,et al.Drug overdose deaths in the United States, 1999–2020. NCHS Data Brief2021; 1–8.
2.
Glasner-EdwardsSRawsonR. Evidence-based practices in addiction treatment: Review and recommendations for public policy. Health Policy (New York)2010; 97: 93–104.
3.
SerafiniGAdavastroGCanepaG, et al.The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: A systematic review. Int J Mol Sci2018; 19: 2410.
4.
HserYIZhuYFeiZ, et al.Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction2022; 117: 151–161.
5.
JonesCMLoganJGladdenRM,et al.Vital signs: Demographic and substance use trends among heroin users—United States, 2002–2013. Morb Mortal Wkly Rep2015; 64: 719.
6.
AmiriSMcDonellMGDenneyJT, et al.Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: A US nationwide small area analysis. Value Heal2021; 24: 188–195.
7.
AndrillaCHAMooreTEPattersonDG,et al.Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. J Rural Heal2019; 35: 108–112.
8.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). 2021.
9.
JonesCMMcCance-KatzEF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend2019; 197: 78–82.
10.
PantanowitzLDickinsonKEvansAJ, et al.American Telemedicine Association clinical guidelines for telepathology. J Pathol Inform2014; 5: 39.
ChanBBougatsosCPriestKC, et al.Opioid treatment programs, telemedicine and COVID-19: A scoping review. Subst Abus2022; 43: 539–546.
13.
LinL (Allison)CasteelDShigekawaE, et al.Telemedicine-delivered treatment interventions for substance use disorders: A systematic review. J Subst Abuse Treat2019; 101: 38–49.
14.
YoungLB. Telemedicine interventions for substance-use disorder: A literature review. J Telemed Telecare2012; 18: 47–53.
15.
SekhonMCartwrightMFrancisJJ. Acceptability of healthcare interventions: An overview of reviews and development of a theoretical framework. BMC Health Serv Res2017; 17: 1–13.
16.
AlhassanRKDukuSOJanssensW, et al.Comparison of perceived and technical healthcare quality in primary health facilities: Implications for a sustainable National Health Insurance Scheme in Ghana. PLoS One2015; 10: e0140109.
17.
Abbasi-MoghaddamMAZareiEBagherzadehR, et al.Evaluation of service quality from patients’ viewpoint. BMC Health Serv Res2019; 19: 1–7.
18.
LevesqueJ-FHarrisMFRussellG. Patient-centred access to health care: Conceptualising access at the interface of health systems and populations. Int J Equity Health2013; 12: 1–9.
19.
SohnHTuckerAFergusonO, et al.Costing the implementation of public health interventions in resource-limited settings: A conceptual framework. Implement Sci2020; 15: 1–8.
20.
U.S. Drug Enforcement Agency Diversion Control Division. COVID-19 information page. Published 2020. Accessed July 25, 2022. https:%0A//www.deadiversion.usdoj.gov/coronavirus.html.
Uscher-PinesLAroraNJonesM, et al.Experiences of health centers in implementing telehealth visits for underserved patients during the COVID-19 pandemic. Published online 2022.
23.
MunnZPetersMDJSternC, et al.Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol2018; 18: 1–7.
24.
LinCPhamHZhuY, et al.Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug Alcohol Depend. Published online2022; 242: 109711.
25.
LevacDColquhounHO’BrienKK. Scoping studies: Advancing the methodology. Implement Sci2010; 5: 1–9.
26.
TriccoACLillieEZarinW, et al.PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med2018; 169: 467–473.
27.
OuzzaniMHammadyHFedorowiczZ,et al.Rayyan—A web and mobile app for systematic reviews. Syst Rev2016; 5: 1–10.
28.
KarwayGIvanovaJBhowmikA, et al.Recommendations to inform substance use disorder data sharing research: Scoping review and thematic analysis. J Addict Med2006; 16: 261–271.
29.
BraunVClarkeV. Using thematic analysis in psychology. Qual Res Psychol2006; 3: 77–101.
30.
TongAFlemmingKMcInnesE, et al.Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol2012; 12: 1–8.
31.
BrunetNMooreDTLendvai WischikD, et al.Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abus2020: 1–8. Published online 2020. doi:10.1080/08897077.2020.1728466.
32.
Uscher-PinesLRajaPMehrotraA,et al.Health center implementation of telemedicine for opioid use disorders: A qualitative assessment of adopters and nonadopters. J Subst Abuse Treat2020; 115: 108037.
33.
MolfenterTRogetNChapleM, et al.Use of telehealth in substance use disorder services during and after COVID-19: Online survey study. JMIR Ment Heal2021; 8: e25835.
34.
RiedelLUscher-PinesLMehrotraA, et al.Use of telemedicine for opioid use disorder treatment—Perceptions and experiences of opioid use disorder clinicians. Drug Alcohol Depend2021; 228: 108999.
35.
HuskampHARiedelLUscher-PinesL, et al.Initiating opioid use disorder medication via telemedicine during COVID-19: Implications for proposed reforms to the Ryan Haight Act. J Gen Intern Med2022; 37: 162–167.
36.
MattocksKMMooreDTWischikDL, et al.Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic. J Subst Abuse Treat2022; 139: 108777.
37.
Uscher-PinesLSousaJRajaP, et al.Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat2020; 118: 108124.
38.
AronowitzSVEngel-RebitzerEDolanA, et al.Telehealth for opioid use disorder treatment in low-barrier clinic settings: An exploration of clinician and staff perspectives. Harm Reduct J2021; 18: 119.
39.
JonesCMDialloMMVythilingamM, et al.Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. Drug Alcohol Depend2021; 225: 108783.
40.
KingVLBroonerRKPeirceJM, et al.A randomized trial of web-based videoconferencing for substance abuse counseling. J Subst Abuse Treat2014; 46: 36–42.
41.
TarpKMejldalANielsenAS. Patient satisfaction with videoconferencing-based treatment for alcohol use disorders. Addict Disord Their Treat2017; 16: 70.
42.
RakitaUGiacobbePCavacuitiC. Opioid use disorder patients’ perceptions of healthcare delivery platforms. SAGE OPEN Med2016; 4: 2050312116670405.
43.
Staton-TindallMHavensJRWebsterJM,et al.METelemedicine: A pilot study with rural alcohol users on community supervision. J Rural Heal2014; 30: 422–432.
44.
LaBelleBFranklynAMNguyen VickyPKH, et al.Characterizing the use of telepsychiatry for patients with opioid use disorder and cooccurring mental health disorders in Ontario, Canada. Int J Telemed Appl2018; 2018: 7937610.
45.
WeintraubEGreenblattADChangJ, et al.Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict2018; 27: 612–617.
46.
EiblJKGauthierGPellegriniD, et al.The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend2017; 176: 133–138.
47.
MitchellMMMendelsonJGryczynskiJ, et al.A novel telehealth platform for alcohol use disorder treatment: Preliminary evidence of reductions in drinking. Am J Drug Alcohol Abuse2020; 46: 297–303.
48.
SugarmanDEBuschABMcHughRK, et al.Patients’ perceptions of telehealth services for outpatient treatment of substance use disorders during the COVID-19 pandemic. Am J Addict2021; 30: 445–452.
49.
PattonEWSaiaKSteinMD. Integrated substance use and prenatal care delivery in the era of COVID-19. J Subst Abuse Treat2021; 124: 108273.
50.
MooreDJGoyalDRodriguezL. Experiences of opioid use disorder patients receiving buprenorphine through a telehealth program. J Addict Nurs2021; 32: 205–210.
51.
KangAWDeBritzAAHoadleyA, et al.Barriers and poor telephone counseling experiences among patients receiving medication for opioid use disorders. Patient Educ Couns2022; 105: 2607–2610.
52.
Zhen-DuanJGadeNFalgas-BaguéI, et al.Using a structural vulnerability framework to understand the impact of COVID-19 on the lives of Medicaid beneficiaries receiving substance use treatment in New York City. Health Serv Res2022; 57: 1104–1111.
53.
MartinRKangAWDe BritzAA, et al.Medication for opioid use disorder service provision and telephone counseling: A concurrent mixed-methods approach. Int J Environ Res Public Health2021; 18: 6163.
54.
GuilleCSimpsonANDouglasE, et al.Treatment of opioid use disorder in pregnant women via telemedicine: A nonrandomized controlled trial. JAMA Netw Open2020; 3: e1920177.
ZhengWNickaschMLanderL, et al.Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: A 2-year retrospective data analysis. J Addict Med2017; 11: 138–144.
57.
WeintraubESeneviratneCAnaneJ, et al.Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. JAMA Netw Open2021; 4: e21118487.
58.
TofighiBMcNeelyJWalzerD, et al.A telemedicine buprenorphine clinic to serve New York City: Initial evaluation of the NYC public hospital system’s initiative to expand treatment access during the COVID-19 pandemic. J Addict Med2022; 16: E40–E43.
59.
CunninghamCOKhalidLDengY, et al.A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. J Subst Abuse Treat2022; 135: 108641.
60.
YeoEJKrallesHSternbergD, et al.Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C. Harm Reduct J2021; 18: 1–7.
61.
Uscher-PinesLCantorJHuskampHA, et al.Adoption of telemedicine services by substance abuse treatment facilities in the U.S. J Subst Abuse Treat2020; 117: 108060.
62.
CantorJLauritoA. The new services that opioid treatment programs have adopted in response to COVID-19. J Subst Abuse Treat2021; 130: 108393.
63.
HuskampHARiedelLUscher-PinesL, et al.Initiating opioid use disorder medication via telemedicine during COVID-19: Implications for proposed reforms to the Ryan Haight Act. J Gen Intern Med2021. Published online October 28, 2021; 1–6. doi:10.1007/S11606-021-07174-W
64.
LinLAFortneyJCBohnertASB, et al.Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. J Subst Abuse Treat2022; 133: 108492.
65.
HuskampHABuschABSouzaJ, et al.How is telemedicine being used in opioid and other substance use disorder treatment?Health Aff2018; 37: 1940–1947.
66.
CreedonTBSchraderKEO’BrienPL, et al.Rural-nonrural differences in telemedicine use for mental and substance use disorders among Medicaid beneficiaries. Psychiatr Serv2020; 71: 756–764.
67.
HughesPMVerrastroGFuscoCW, et al.An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. J Rural Heal2021; 37: 467–472.
68.
CanceJDDoyleE. Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic. JAMA - J Am Med Assoc2020; 324: 2442–2444.
69.
ChangJELindenfeldZThomasT, et al.Patient characteristics associated with phone versus video telemedicine visits for substance use treatment during COVID-19. J Addict Med2022; 16: 659–665.
70.
FaragherJMZhangYSDLowV, et al.Utilization of telehealth technology in addiction treatment in Colorado. J Technol Behav Sci2018; 3: 226–246.
71.
GresslerLENatafgiNMDeForgeB, et al.What motivates people with substance use disorders to pursue treatment? A patient-centered approach to understanding patient experiences and patient-provider interactions. J Subst Use2019; 24: 587–599.
72.
AndreasJBLauritzenGNordfjærnT. Co-occurrence between mental distress and poly-drug use: A ten year prospective study of patients from substance abuse treatment. Addict Behav2015; 48: 71–78.
73.
LinLABohnertASBBlowFC, et al.Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction2021; 116: 96–104.
74.
AyalaGXElderJP. Qualitative methods to ensure acceptability of behavioral and social interventions to the target population. J Public Health Dent2011; 71: S69–S79.
75.
HerbertRDKaszaJBøK. Analysis of randomised trials with long-term follow-up. BMC Med Res Methodol2018; 18: 1–9.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
